



## Authors' corrections for Can Commun Dis Rep. 2016;42(11)

M Ebrahim<sup>1</sup>, D Gravel<sup>1\*</sup>, C Thabet<sup>1</sup>, K Abdesselam<sup>1</sup>, S Paramalingam<sup>1</sup>, C Hyson<sup>1</sup>

### Affiliation

<sup>1</sup> Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON

\*Correspondence: [denise.graveltropper@phac-aspc.gc.ca](mailto:denise.graveltropper@phac-aspc.gc.ca)

**Suggested citation:** Ebrahim M, Gravel D, Thabet C, Abdesselam K, Paramalingam S, Hyson C. Correction for Can Commun Dis Rep. 2016;42(11). Can Commun Dis Rep. 2017;43(2):61.

In the article "[Antimicrobial use and antimicrobial resistance trends in Canada: 2014](http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/16vol42/dr-rm42-11/ar-02-eng.php)" (1) (<http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/16vol42/dr-rm42-11/ar-02-eng.php>) by Ebrahim M et al published on November 3, 2016, the following corrections were made on February 2, 2017 upon the request of the authors:

1. In the Results, in the "Antibiotic use" section, under the sub-heading "Usage in food production animals" the following two sentences:

"Due to a new indication for use for fluoroquinolone in animals, the quantity of fluoroquinolones distributed increased by 14% between 2013 and 2014. However there has been an overall 40% increase since 2010."

were changed to:

"Since 2010 there has been a 40% increase in the quantity of fluoroquinolones distributed for use in animals, likely due in part to the approval of a new indication for fluoroquinolone use. Between 2013 and 2014, the quantity increased by 14%."

2. At the end of the Acknowledgements the following sentence was added:

The authors would also like to acknowledge with thanks the Canadian Antimicrobial Resistance Surveillance System (CARSS) team for the creation of materials and Figures used in this summary.

### Reference

1. Ebrahim M, Gravel D, Thabet C, Abdesselam K, Paramalingam S, Hyson C. [Antimicrobial use and antimicrobial resistance trends in Canada: 2014](http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/16vol42/dr-rm42-11/ar-02-eng.php). Can Commun Dis Rep. 2016;42(11):227-31. Available from: <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/16vol42/dr-rm42-11/ar-02-eng.php>.

## CCDR correction for Can Commun Dis Rep. 2017;43(1)

Canada Communicable Disease Report Editorial team<sup>1\*</sup>

### Affiliation

<sup>1</sup> CCDR Editorial Office, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada Ottawa, ON

\*Correspondence: [ccdr-rmtc@phac-aspc.gc.ca](mailto:ccdr-rmtc@phac-aspc.gc.ca)

**Suggested citation:** Canada Communicable Disease Report Editorial team. Correction for Can Commun Dis Rep. 2017;43(1). Can Commun Dis Rep. 2017;43(2):61.

In the Editorial Policy article "[Information for Authors: 2017](http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/17vol43/dr-rm43-1/ar-06-eng.php)" (1) (<http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/17vol43/dr-rm43-1/ar-06-eng.php>) published on January 5, 2017, the following correction was made on February 2, 2017:

1. In "The editorial and production process" section, under the sub-heading "Assessment and revision", the sentence:

"Manuscripts that have been correctly submitted are screened by the editorial team for appropriateness and assessed with iThenticate<sup>12</sup> software for redundancy."

was changed to:

"Manuscripts that have been correctly submitted are assessed by the editorial team for appropriateness and will soon be routinely screened with antiplagiarism software."

and footnote 12 was removed.

### Reference

1. Canadian Communicable Disease Report Editorial Office. [Information for Authors: 2017](http://webqa.phac-aspc.gc.ca/publicat/ccdr-rmtc/17vol43/dr-rm43-1/ar-06-eng.php). Can Commun Dis Rep. 2017;43(1):32-4. Available from: <http://webqa.phac-aspc.gc.ca/publicat/ccdr-rmtc/17vol43/dr-rm43-1/ar-06-eng.php>.